Argos Therapeutics Company

Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Technology: Transplantation
Industry: Regenerative medicine
Headquarters: Others
Founded Date: 1997-01-01
Employees Number: 101-250
Funding Status: IPO

Visit Website
social@argostherapeutics.com
https://twitter.com/argosthera
Register and Claim Ownership